id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-D-2565-0036,FDA,FDA-2016-D-2565,"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review; Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations",Other,Guidance,2024-11-21T05:00:00Z,2024,11,2024-11-21T05:00:00Z,,2024-11-21T14:12:37Z,,1,0,090000648682bfa0
FDA-2016-D-2565-0035,FDA,FDA-2016-D-2565,"510(k) Third Party Review Program and Third Party Emergency Use Authorization Review; Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations; Availability",Notice,Notice of Availability,2024-11-21T05:00:00Z,2024,11,,,2024-11-21T14:14:28Z,2024-27085,0,0,090000648682c244